EGFR tyrosine kinase inhibitor erlotinib exhibits antimetastatic activity against inflammatory breast cancer

被引：0
|
作者：
Ueno, Naoto [1 ]
LaFortune, Tiffany [1 ]
Hortobagyi, Gabriel [1 ]
Lucci, Anthony [1 ]
Singh, Balraj [1 ]
Krishnamurthy, Savitri [1 ]
Esteva, Francisco [1 ]
Hung, Mien-Chie [1 ]
Zhang, Dongwei [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1767
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation
    Becker, Kevin
    Xu, Yiqing
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2014, 5 (04): : 560 - 567
  • [22] EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells
    Mallmann-Gottschalk, Nina
    Sax, Yvonne
    Kimmig, Rainer
    Lang, Stephan
    Brandau, Sven
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (19)
  • [23] MP-412, a dual EGFR/HER2 tyrosine kinase inhibitor shows antitumor activity against both Erlotinib/Gefitinib-sensitive and resistant EGFR mutations in human lung cancer xenograft models
    Fujii, Akihiro
    Suzuki, Tsuyoshi
    Ohya, Jun-Ichi
    Nakamura, Hideo
    CANCER RESEARCH, 2006, 66 (08)
  • [24] Anti-tumor activity of a novel EGFR tyrosine kinase inhibitor against human NSCLC in vitro and in vivo
    Li, Jing
    Li, Yan
    Feng, Zhi-qiang
    Chen, Xiao-guang
    CANCER LETTERS, 2009, 279 (02) : 213 - 220
  • [25] Antitumor efficacy of ZD6474, a VEGFR tyrosine kinase signaling inhibitor with additional activity against EGFR tyrosine kinase, alone and in combination with radiotherapy in human head and neck cancer
    Raben, D
    Gustafson, DL
    Frederick, B
    Merz, AL
    Zirrolli, JA
    LUNG CANCER, 2004, 46 : S24 - S25
  • [26] Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib
    Guttman-Yassky, Emma
    Mita, Alain
    De Jong, Maja
    Matthews, Lesley
    McCarthy, Sean
    Iwata, Kenneth K.
    Verweij, Jaap
    Rowinsky, Eric K.
    Krueger, James G.
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (11) : 2010 - 2019
  • [27] Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models
    Chen, Jianping
    Smith, Melissa
    Kolinsky, Kenneth
    Adames, Violeta
    Mehta, Nila
    Fritzky, Luke
    Rashed, Mohammad
    Wheeldon, Eric
    Linn, Michael
    Higgins, Brian
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (05) : 651 - 659
  • [28] In Vitro Antimetastatic Activity of Koetjapic Acid against Breast Cancer Cells
    Nassar, Zeyad D.
    Aisha, Abdalrahim F. A.
    Al Suede, Fouad Saleih R.
    Majid, Aman Shah Abdul
    Majid, Amin Malik Shah Abdul
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2012, 35 (04) : 503 - 508
  • [29] Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models
    Jianping Chen
    Melissa Smith
    Kenneth Kolinsky
    Violeta Adames
    Nila Mehta
    Luke Fritzky
    Mohammad Rashed
    Eric Wheeldon
    Michael Linn
    Brian Higgins
    Cancer Chemotherapy and Pharmacology, 2007, 59 : 651 - 659
  • [30] ZD6474 - a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
    Ryan, AJ
    Wedge, SR
    BRITISH JOURNAL OF CANCER, 2005, 92 (Suppl 1) : S6 - S13
12345